From Data to Resolution: How AI Is Reshaping Healthcare. A post-event synthesis of the ideas, evidence, debates and practical recommendations shared by healthcare, life sciences and technology leaders in Princeton.
The summit brought together leaders from healthcare systems, life sciences, pharma, academia and enterprise technology to examine how AI is reshaping research, clinical care, health-benefit operations, commercial strategy and regulatory practice.
Across the day, presenters consistently shifted the conversation away from whether organizations should adopt AI and toward how they can govern it, measure it, scale it and preserve human accountability. Agentic AI is already operating in real healthcare workflows, but its long-term value depends on transparent design, privacy engineering, strong operating models and a clear intelligence layer beneath the interface.
Rather than a simple recap, the report connects the summit’s talks and panels into a practical narrative about research, clinical trust, enterprise governance, operations, ROI and regulation.
William Mayo challenged the industry’s “Data Delusion” and called for a shift from empirical discovery toward physics-grounded resolution models and Large Quantitative Models.
Takeaway: biology needs theoretical infrastructure to match its data ambitions.
Jon Lilly focused on the risks created by enterprise LLMs, copilots, embedded SaaS AI and agents already operating inside organizations.
Takeaway: usable governance and deliberate configuration are prerequisites, not afterthoughts.
Paul Wojnicki presented an approach that normalizes clinical data, supports multilingual queries and forecasts patient trajectories while keeping clinicians accountable.
Takeaway: practical clinical AI depends on citations, transparency and clinician review.
Amit Srivastava used prior authorization to show how custom document-understanding models can manage complex, compliance-heavy healthcare workflows at production scale.
Takeaway: well-scoped agentic AI can deliver high accuracy with deliberate data engineering.
Panelists connected privacy engineering, responsible governance and clinical modernization to the realities of scaling AI across regulated organizations.
Takeaway: privacy-by-design and cross-functional ownership must begin on day one.
Leaders discussed cloud strategy, operating models, adoption metrics and how to translate technical success into measurable business and patient outcomes.
Takeaway: executive buy-in follows measurable impact and board-defensible operating models.
Anupam Nandwana argued that the agent itself is not the differentiator; durable value comes from persistent memory, therapeutic specificity and built-in compliance.
Takeaway: invest in intelligence that compounds, not an interface competitors can also buy.
The closing panel examined deployment realities, FDA guidance, equity, academic translation and the need to augment rather than replace human expertise.
Takeaway: responsible progress requires regulatory evolution and equity by design.
Talk tracks, moderated panels, networking and practical discussions spanning the lab, the bedside and the boardroom.
Regardless of whether the discussion began in a research lab, compliance office, clinical setting or pharma boardroom, the same principles returned repeatedly.
Move beyond brute-force data collection toward structured, theory-grounded approaches.
Model capability is advancing faster than the policies and operating structures needed to scale it safely.
The next question is no longer whether agents will arrive, but what intelligence and controls sit beneath them.
AI should augment clinicians, representatives and analysts while keeping a person accountable for outcomes.
Measurable outcomes, governance and cross-functional ownership are essential for durable investment.
Five actions drawn directly from the day’s sessions and discussions.
Map enterprise chat, copilots, embedded SaaS AI, specialty AI and agentic AI separately. Most organizations operate at several levels at once.
Establish approved use cases, vendor diligence, configuration standards and clear accountability before adoption accelerates.
Keep a human accountable, make reasoning traceable and treat transparency as a product requirement.
Persistent memory, domain specificity and compounding value create differentiation—not simply deploying another agent.
ROI conversations become credible when governance, ownership and measurable outcomes are designed from the start.
Speakers, panel discussions, technical presentations, networking and the community that made the HealthIQ AI Summit possible.
Confliq thanks every speaker, panelist, moderator, sponsor and attendee who made the 2026 summit possible. The next Confliq event is already taking shape. Organizations interested in speaking, sponsoring or attending are invited to connect with us.